- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) - - AFM28 shows single agent efficacy with 2 CR/CRi and 3 stable disease (SD) in 6 patients treated at dose level of 300 mg weekly - Acimtamig (AFM13) combination with AlloNK® (AB-101) natural killer (NK) cells: Recruitment in cohorts 1 and 2 completed. In the first 7 treatment refractory Hodgkin Lymphoma (HL) patients, an ORR of 85.7% observed, with 4 CRs and ...

- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) - - AFM28 shows single agent efficacy with 2 CR/CRi and 3 stable disease (SD) in 6 patients treated at dose level of 300 mg weekly - Acimtamig (AFM13) combination with AlloNK® (AB-101) natural killer (NK) cells: Recruitment in cohorts 1 and 2 completed. In the first 7 treatment refractory Hodgkin Lymphoma (HL) patients, an ORR of 85.7% observed, with 4 CRs and ...

MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2024 results and corporate update on Wednesday, June 12, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" se ...

MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical- stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2024 results and corporate update on Wednesday, June 12, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “Webcasts” ...

Affimed N.V. (AFMD) surged 68.5% after the company reported follow-up efficacy data from the EGFR wild- type (EGFRwt) cohort and initial clinical efficacy data from the EGFR mutant (EGFRmut) cohort of the ongoing early to mid-stage study of AFM24 to treat non-small cell lung cancer (NSCLC) patients. The phase I/IIa AFM24-102 study is evaluating AFM24 in combination with Roche’s (RHHBY) immuno- oncology drug, Tecentriq (atezolizumab), in heavily pre-treated NSCLC patients. Please note that the company first ...

In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing for more than 7 months and progression free survival (PFS) was 5.9 months Objective responses were also seen in 4 of 13 response-evaluable EGFR mutant (EGFRmut) NSCLC patients confirming the activity of AFM24 and atezolizumab in heavily pretreated NSCLC patients In both NSCLC cohorts, the combination therapy sh ...

Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/metastatic cancers in the ongoing AFM24-102 phase 1/2a study The FDA's Fast Track designation was granted after its review of the initial efficacy data of the EGFR wild-type cohort from the AFM24-102 study Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious con ...

MANNHEIM, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2024 Annual General Meeting of Shareholders (the “Annual Meeting”) will be held on June 26, 2024 at 09:00 a.m. CET at the offices of De Brauw Blackstone Westbroek N.V., Burgerweeshuispad 201, 1076 GR Amsterdam, the Netherlands. The notice and agenda of the Annual ...

One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks. Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points. Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many upstart biotech firms fail to co ...

In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led to a disease control rate of 73.3% (11/15), including 4 objective responses (1 complete and 3 partial responses) As of the March 18, 2024 data cut-off, the median progression free survival was 5.9 months and 3 of 4 responses were ongoing The poster of the ongoing study will be presented on June 1, 2024, 9:00 a. ...